Targeting proteinase-activated receptors: Therapeutic potential and challenges

Nature Reviews Drug Discovery

Volumn 11, Issue 1, 2012, Pages 69-86

  Ramachandran, Rithwik ^a   Noorbakhsh, Farshid ^a,b   Defea, Kathryn ^c   Hollenberg, Morley D ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (ETHOXYCARBONYLPHENYL)INDAZOLE; AC 264613; AC 55541; ACETYLSALICYLIC ACID; ATOPAXAR; BETA ARRESTIN 2; BMS 200261; ENMD 1068; F 16357; F 16618; FR 17113; G PROTEIN COUPLED RECEPTOR KINASE 3; G PROTEIN COUPLED RECEPTOR KINASE 5; GB 88; GUANINE NUCLEOTIDE BINDING PROTEIN; K 14585; MITOGEN ACTIVATED PROTEIN KINASE; PROTEINASE ACTIVATED RECEPTOR; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 2; PROTEINASE ACTIVATED RECEPTOR 3; PROTEINASE ACTIVATED RECEPTOR 4; PROTEINASE ACTIVATED RECEPTOR BLOCKING AGENT; RECEPTOR BLOCKING AGENT; RWJ 56110; RWJ 58259; TACHYKININ RECEPTOR ANTAGONIST; THROMBIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORAPAXAR; YD 3;

ACUTE CORONARY SYNDROME; ARTHRITIS; ASTHMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; COLITIS; CORONARY ARTERY DISEASE; DRUG STRUCTURE; DRUG TARGETING; GASTROINTESTINAL TRACT; HEART INFARCTION; HUMAN; INTERNALIZATION; NEOPLASM; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; RESPIRATORY SYSTEM; REVIEW; SIGNAL TRANSDUCTION; STROKE; THROMBOCYTE FUNCTION; THROMBOSIS;

ANIMALS; DRUG DELIVERY SYSTEMS; GUANIDINES; HUMANS; NEOPLASMS; OLIGOPEPTIDES; PHARMACEUTICAL PREPARATIONS; RECEPTORS, PROTEINASE-ACTIVATED;

EID: 84855376225     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3615     Document Type: Review

References (235)

1. Rieser, P. The insulin-like action of pepsin and pepsinogen. Acta Endocrinol. 54, 375-379 (1967).
2. Rieser, P. & Rieser, C. H. Anabolic responses of diaphragm muscle to insulin and to other pancreatic proteins. Proc. Soc. Exp. Biol. Med. 116, 669-671 (1964).
3. Burger, M. M. Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature 227, 170-171 (1970).
4. Sefton, B. M. & Rubin, H. Release from density dependent growth inhibition by proteolytic enzymes. Nature 227, 843-845 (1970).
5. Chen, L. B. & Buchanan, J. M. Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc. Natl Acad. Sci. USA 72, 131-135 (1975).
6. Carney, D. H. & Cunningham, D. D. Transmembrane action of thrombin initiates chick cell division. J. Supramol. Struct. 9, 337-350 (1978).
7. Carney, D. H. & Cunningham, D. D. Initiation of chick cell division by trypsin action at the cell surface. Nature 268, 602-606 (1977). (Pubitemid 8227845)
8. Coughlin, S. R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J. Thromb. Haemost. 3, 1800-1814 (2005). (Pubitemid 41716567)
9. Ramachandran, R. & Hollenberg, M. D. Proteinases and signalling: pathophysiological and therapeutic implications via PARs and more. Br. J. Pharmacol. 153 (Suppl. 1), 263-282 (2008).
10. Adams, M. N. et al. Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 130, 248-282 (2011).
11. Vu, T. K., Hung., D. T., Wheaton, V. I. & Coughlin, S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057-1068 (1991). (Pubitemid 121001193)
12. Rasmussen, U. B. et al. cDNA cloning and expression of a hamster α-thrombin receptor coupled to Ca2+ mobilization. FEBS Lett. 288, 123-128 (1991).
13. Nystedt, S., Emilsson, K., Wahlestedt, C. & Sundelin, J. Molecular cloning of a potential proteinase activated receptor. Proc. Natl Acad. Sci. USA 91, 9208-9212 (1994). (Pubitemid 24297883)
14. Nystedt, S., Emilsson, K., Larsson, A. K., Strombeck, B. & Sundelin, J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur. J. Biochem. 232, 84-89 (1995).
15. Ishihara, H. et al. Protease-activated receptor 3 is a second thrombin receptor in humans. Nature 386, 502-506 (1997). (Pubitemid 27164077)
16. Kahn, M. L. et al. A dual thrombin receptor system for platelet activation. Nature 394, 690-694 (1998). (Pubitemid 28389797)
17. Xu, W. F. et al. Cloning and characterization of human protease-activated receptor 4. Proc. Natl Acad. Sci. USA 95, 6642-6646 (1998).
18. Nakanishi-Matsui, M. et al. PAR3 is a cofactor for PAR4 activation by thrombin. Nature 404, 609-613 (2000).
19. McLaughlin, J. N., Patterson, M. M. & Malik, A. B. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization. Proc. Natl Acad. Sci. USA 104, 5662-5667 (2007). (Pubitemid 47175737)
20. Scarborough, R. M. et al. Tethered ligand agonist peptides. Structural requirements for thrombin receptor activation reveal mechanism of proteolytic unmasking of agonist function. J. Biol. Chem. 267, 13146-13149 (1992).
21. Hollenberg, M. D., Saifeddine, M., Al-Ani, B. & Kawabata, A. Proteinase-activated receptors: structural requirements for activity, receptor cross-reactivity, and receptor selectivity of receptor-activating peptides. Can. J. Physiol. Pharmacol. 75, 832-841 (1997). (Pubitemid 27451801)
22. McGuire, J. J., Dai, J., Andrade-Gordon, P., Triggle, C. R. & Hollenberg, M. D. Proteinase-activated receptor-2 (PAR2): vascular effects of a PAR2-derived activating peptide via a receptor different than PAR2. J. Pharmacol. Exp. Ther. 303, 985-992 (2002). (Pubitemid 35424380)
23. Liu, Q. et al. The distinct roles of two GPCRs, MrgprC11 and PAR2, in itch and hyperalgesia. Sci. Signal. 4, ra45 (2011).
24. Defea, K. β-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction. Br. J. Pharmacol. 153 (Suppl. 1), 298-309 (2008).
25. Dulon, S. et al. Proteinase-activated receptor-2 and human lung epithelial cells: disarming by neutrophil serine proteinases. Am. J. Respir. Cell. Mol. Biol. 28, 339-346 (2003). (Pubitemid 36238011)
26. Renesto, P. et al. Specific inhibition of thrombin-induced cell activation by the neutrophil proteinases elastase, cathepsin G, and proteinase 3: evidence for distinct cleavage sites within the aminoterminal domain of the thrombin receptor. Blood 89, 1944-1953 (1997). (Pubitemid 27132109)
27. Ramachandran, R. et al. Neutrophil elastase acts as a biased agonist for proteinase activated receptor-2 (PAR2). J. Biol. Chem. 286, 24638-24648 (2011).
28. Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seven-transmembrane receptors. Nature Rev. Drug Discov. 9, 373-386 (2011).
29. Kenakin, T. & Miller, L. J. Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery. Pharmacol. Rev. 62, 265-304 (2010).
30. Kenakin, T. Functional selectivity and biased receptor signaling. J. Pharmacol. Exp. Ther. 336, 296-302 (2011).
31. Shapiro, M. J., Trejo, J., Zeng, D. & Coughlin, S. R. Role of the thrombin receptor's cytoplasmic tail in intracellular trafficking. Distinct determinants for agonist-triggered versus tonic internalization and intracellular localization. J. Biol. Chem. 271, 32874-32880 (1996).
32. Shapiro, M. J. & Coughlin, S. R. Separate signals for agonist-independent and agonist-triggered trafficking of protease-activated receptor 1. J. Biol. Chem. 273, 29009-29014 (1998). (Pubitemid 28507596)
33. Ishii, K. et al. Inhibition of thrombin receptor signaling by a G-protein coupled receptor kinase. Functional specificity among G-protein coupled receptor kinases. J. Biol. Chem. 269, 1125-1130 (1994).
34. Tiruppathi, C. et al. G protein-coupled receptor kinase-5 regulates thrombin-activated signaling in endothelial cells. Proc. Natl Acad. Sci. USA 97, 7440-7445 (2000). (Pubitemid 30431482)
35. Wolfe, B. L., Marchese, A. & Trejo, J. Ubiquitination differentially regulates clathrin-dependent internalization of protease-activated receptor-1. J. Cell Biol. 177, 905-916 (2007). (Pubitemid 46873095)
36. Paing, M. M., Johnston, C. A., Siderovski, D. P. & Trejo, J. Clathrin adaptor AP2 regulates thrombin receptor constitutive internalization and endothelial cell resensitization. Mol. Cell Biol. 26, 3231-3242 (2006).
37. Paing, M. M., Stutts, A. B., Kohout, T. A., Lefkowitz, R. J. & Trejo, J. β-arrestins regulate protease-activated receptor-1 desensitization but not internalization or down-regulation. J. Biol. Chem. 277, 1292-1300 (2002). (Pubitemid 34968882)
38. Chen, B. et al. Adaptor protein complex-2 (AP-2) and epsin-1 mediate protease-activated receptor-1 internalization via phosphorylation-and ubiquitination-dependent sorting signals. J. Biol. Chem. 286, 40760-40770 (2011).
39. Bohm, S. K. et al. Mechanisms of desensitization and resensitization of proteinase-activated receptor-2. J. Biol. Chem. 271, 22003-22016 (1996). (Pubitemid 26303826)
40. Seatter, M. J. et al. The role of the C-terminal tail in protease-activated receptor-2-mediated Ca2+ signalling, proline-rich tyrosine kinase-2 activation, and mitogen-activated protein kinase activity. Cell Signal. 16, 21-29 (2004). (Pubitemid 37357188)
41. Ricks, T. K. & Trejo, J. Phosphorylation of protease-activated receptor-2 differentially regulates desensitization and internalization. J. Biol. Chem. 284, 34444-34457 (2009).
42. Dery, O., Thoma, M. S., Wong, H., Grady, E. F. & Bunnett, N. W. Trafficking of proteinase-activated receptor-2 and β-arrestin-1 tagged with green fluorescent protein. β-arrestin-dependent endocytosis of a proteinase receptor. J. Biol. Chem. 274, 18524-18535 (1999).
43. Hasdemir, B., Murphy, J. E., Cottrell, G. S. & Bunnett, N. W. Endosomal deubiquitinating enzymes control ubiquitination and down-regulation of protease-activated receptor 2. J. Biol. Chem. 284, 28453-28466 (2009).
44. Hasdemir, B., Bunnett, N. W. & Cottrell, G. S. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS) mediates post-endocytic trafficking of protease-activated receptor 2 and calcitonin receptor-like receptor. J. Biol. Chem. 282, 29646-29657 (2007). (Pubitemid 350043395)
45. Shapiro, M. J., Weiss, E. J., Faruqi, T. R. & Coughlin, S. R. Protease-activated receptors 1 and 4 are shut off with distinct kinetics after activation by thrombin. J. Biol. Chem. 275, 25216-25221 (2000).
46. Li, D., D'Angelo, L., Chavez, M. & Woulfe, D. S. Arrestin-2 differentially regulates PAR4 and ADP receptor signaling in platelets. J. Biol. Chem. 286, 3805-3814 (2011).
47. Jacobs, S. & Cuatrecasas, P. The mobile receptor hypothesis and "cooperativity" of hormone binding. Application to insulin. Biochim. Biophys. Acta 433, 482-495 (1976).
48. de Haen, C. The non-stoichiometric floating receptor model for hormone sensitive adenylyl cyclase. J. Theor. Biol. 58, 383-400 (1976).
49. Urban, J. D. et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320, 1-13 (2007). (Pubitemid 46025713)
50. McLaughlin, J. N. et al. Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J. Biol. Chem. 280, 25048-25059 (2005). (Pubitemid 40934596)
51. Russo, A., Soh, U. J., Paing, M. M., Arora, P. & Trejo, J. Caveolae are required for protease-selective signaling by protease-activated receptor-1. Proc. Natl Acad. Sci. USA 106, 6393-6397 (2009).
52. Awasthi, V., Mandal, S. K., Papanna, V., Rao, L. V. & Pendurthi, U. R. Modulation of tissue factor-factor VIIa signaling by lipid rafts and caveolae. Arterioscler. Thromb. Vasc. Biol. 27, 1447-1455 (2007). (Pubitemid 46809437)
53. Hamilton, J. R., Nguyen, P. B. & Cocks, T. M. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human coronary arteries. Circ. Res. 82, 1306-1311 (1998). (Pubitemid 28294750)
54. Roy, S. S., Saifeddine, M., Loutzenhiser, R., Triggle, C. R. & Hollenberg, M. D. Dual endothelium-dependent vascular activities of proteinase-activated receptor-2-activating peptides: evidence for receptor heterogeneity. Br. J. Pharmacol. 123, 1434-1440 (1998). (Pubitemid 28143145)
55. Ballerio, R. et al. Distinct roles for PAR1-and PAR2-mediated vasomotor modulation in human arterial and venous conduits. J. Thromb. Haemost. 5, 174-180 (2007). (Pubitemid 44921083)
56. Hamilton, J. R., Frauman, A. G. & Cocks, T. M. Increased expression of protease-activated receptor-2 (PAR2) and PAR4 in human coronary artery by inflammatory stimuli unveils endothelium-dependent relaxations to PAR2 and PAR4 agonists. Circ. Res. 89, 92-98 (2001). (Pubitemid 34135497)
57. Moffatt, J. D. & Cocks, T. M. Endothelium-dependent and-independent responses to protease-activated receptor-2 (PAR-2) activation in mouse isolated renal arteries. Br. J. Pharmacol. 125, 591-594 (1998). (Pubitemid 28482594)
58. Laniyonu, A. A. & Hollenberg, M. D. Vascular actions of thrombin receptor-derived polypeptides: structure-activity profiles for contractile and relaxant effects in rat aorta. Br. J. Pharmacol. 114, 1680-1686 (1995).
59. Kagota, S., Chia, E. & McGuire, J. J. Preserved arterial vasodilation via endothelial protease-activated receptor-2 in obese type 2 diabetic mice. Br. J. Pharmacol. 164, 358-371 (2011).
60. McGuire, J. J., Van Vliet, B. N. & Halfyard, S. J. Blood pressures, heart rate and locomotor activity during salt loading and angiotensin II infusion in protease-activated receptor 2 (PAR2) knockout mice. BMC Physiol. 8, 20 (2008).
61. Hirano, K. & Hirano, M. Current perspective on the role of the thrombin receptor in cerebral vasospasm after subarachnoid hemorrhage. J. Pharmacol. Sci. 114, 127-133 (2010).
62. Hollenberg, M. D. Novel insights into the delayed vasospasm following subarachnoid haemorrhage: importance of proteinase signalling. Br. J. Pharmacol. 30 Jun 2011 (doi:10.1111/j.1476-5381.2011.01564.x).
63. Kameda, K. et al. Combined argatroban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid hemorrhage. Br. J. Pharmacol. 13 May 2011 (doi:10.1111/j.1476-5381. 2011.01485.x).
64. Hung., D. T., Vu, T. K., Wheaton, V. I., Ishii, K. & Coughlin, S. R. Cloned platelet thrombin receptor is necessary for thrombin-induced platelet activation. J. Clin. Invest. 89, 1350-1353 (1992).
65. Cook, J. J. et al. An antibody against the exosite of the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation 91, 2961-2971 (1995).
66. Kahn, M. L., Nakanishi-Matsui, M., Shapiro, M. J., Ishihara, H. & Coughlin, S. R. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J. Clin. Invest. 103, 879-887 (1999). (Pubitemid 29152634)
67. Leger, A. J. et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation 113, 1244-1254 (2006).
68. Covic, L., Gresser, A. L. & Kuliopulos, A. Biphasic kinetics of activation and signaling for PAR1 and PAR4 thrombin receptors in platelets. Biochemistry 39, 5458-5467 (2000). (Pubitemid 30257087)
69. Sevigny, L. M. et al. Protease-activated receptor-2 modulates protease-activated receptor-1-driven neointimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 31, e100-e106 (2011).
70. Sambrano, G. R. et al. Cathepsin G activates protease-activated receptor-4 in human platelets. J. Biol. Chem. 275, 6819-6823 (2000). (Pubitemid 30146221)
71. Oikonomopoulou, K. et al. Kallikrein-mediated cell signalling: targeting proteinase-activated receptors (PARs). Biol. Chem. 387, 817-824 (2006). (Pubitemid 43964807)
72. Santulli, R. J. et al. Evidence for the presence of a protease-activated receptor distinct from the thrombin receptor in human keratinocytes. Proc. Natl Acad. Sci. USA 92, 9151-9155 (1995).
73. Oikonomopoulou, K. et al. Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281, 32095-32112 (2006). (Pubitemid 46036764)
74. Cornelissen, I. et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc. Natl Acad. Sci. USA 107, 18605-18610 (2011).
75. Vergnolle, N., Hollenberg, M. D., Sharkey, K. A. & Wallace, J. L. Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 127, 1083-1090 (1999). (Pubitemid 29326629)
76. Vergnolle, N., Hollenberg, M. D. & Wallace, J. L. Pro-and anti-inflammatory actions of thrombin: a distinct role for proteinase-activated receptor-1 (PAR1). Br. J. Pharmacol. 126, 1262-1268 (1999). (Pubitemid 29123764)
77. Asfaha, S., Brussee, V., Chapman, K., Zochodne, D. W. & Vergnolle, N. Proteinase-activated receptor-1 agonists attenuate nociception in response to noxious stimuli. Br. J. Pharmacol. 135, 1101-1106 (2002). (Pubitemid 34259109)
78. Asfaha, S. et al. Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation. Br. J. Pharmacol. 150, 176-185 (2007). (Pubitemid 46160607)
79. Steinhoff, M. et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nature Med. 6, 151-158 (2000). (Pubitemid 30082358)
80. Vergnolle, N. et al. Proteinase-activated receptor-2 and hyperalgesia: A novel pain pathway. Nature Med. 7, 821-826 (2001). (Pubitemid 32691637)
81. Russell, F. A. & McDougall, J. J. Proteinase activated receptor (PAR) involvement in mediating arthritis pain and inflammation. Inflamm. Res. 58, 119-126 (2009).
82. Ferrell, W. R. et al. Essential role for proteinase-activated receptor-2 in arthritis. J. Clin. Invest. 111, 35-41 (2003). (Pubitemid 36134846)
83. Kelso, E. B. et al. Therapeutic promise of proteinase-activated receptor-2 antagonism in joint inflammation. J. Pharmacol. Exp. Ther. 316, 1017-1024 (2006). (Pubitemid 43345273)
84. Howell, D. C. et al. Absence of proteinase-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am. J. Pathol. 166, 1353-1365 (2005). (Pubitemid 40586507)
85. Scotton, C. J. et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J. Clin. Invest. 119, 2550-2563 (2009).
86. Chambers, R. C., Leoni, P., Blanc-Brude, O. P., Wembridge, D. E. & Laurent, G. J. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J. Biol. Chem. 275, 35584-35591 (2000).
87. Chambers, R. C. et al. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem. J. 333 (Pt 1), 121-127 (1998). (Pubitemid 28342501)
88. Bogatkevich, G. S., Tourkina, E., Silver, R. M. & Ludwicka-Bradley, A. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J. Biol. Chem. 276, 45184-45192 (2001).
89. Riewald, M., Petrovan, R. J., Donner, A., Mueller, B. M. & Ruf, W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 296, 1880-1882 (2002). (Pubitemid 34596276)
90. Riewald, M. & Ruf, W. Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J. Biol. Chem. 280, 19808-19814 (2005). (Pubitemid 41379506)
91. Yasui, H. et al. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am. J. Respir. Crit. Care Med. 163, 1660-1668 (2001). (Pubitemid 32578773)
92. Deng, X., Mercer, P. F., Scotton, C. J., Gilchrist, A. & Chambers, R. C. Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Gαq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol. Biol. Cell 19, 2520-2533 (2008).
93. Ando, S. et al. Proteinase-activated receptor 4 stimulation-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir. Res. 8, 31 (2007).
94. Ramachandran, R. et al. Inflammatory mediators modulate thrombin and cathepsin-G signaling in human bronchial fibroblasts by inducing expression of proteinase-activated receptor-4. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L788-L798 (2007). (Pubitemid 46376997)
95. Ramachandran, R., Morice, A. H. & Compton, S. J. Proteinase-activated receptor 2 agonists upregulate granulocyte colony-stimulating factor, IL-8, and VCAM-1 expression in human bronchial fibroblasts. Am. J. Respir. Cell. Mol. Biol. 35, 133-141 (2006). (Pubitemid 43993163)
96. Akers, I. A. et al. Mast cell tryptase stimulates human lung fibroblast proliferation via protease-activated receptor-2. Am. J. Physiol. Lung Cell. Mol. Physiol. 278, L193-L201 (2000). (Pubitemid 30104191)
97. Schmidlin, F. et al. Protease-activated receptor 2 mediates eosinophil infiltration and hyperreactivity in allergic inflammation of the airway. J. Immunol. 169, 5315-5321 (2002). (Pubitemid 35217205)
98. Ebeling, C. et al. Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways. J. Allergy Clin. Immunol. 115, 623-630 (2005). (Pubitemid 40341720)
99. Ebeling, C., Lam, T., Gordon, J. R., Hollenberg, M. D. & Vliagoftis, H. Proteinase-activated receptor-2 promotes allergic sensitization to an inhaled antigen through a TNF-mediated pathway. J. Immunol. 179, 2910-2917 (2007).
100. Arizmendi, N. G. et al. Mucosal allergic sensitization to cockroach allergens is dependent on proteinase activity and proteinase-activated receptor-2 activation. J. Immunol. 186, 3164-3172 (2011).
101. Adam, E. et al. The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism. J. Biol. Chem. 281, 6910-6923 (2006). (Pubitemid 43847453)
102. Asokananthan, N. et al. Activation of protease-activated receptor (PAR)-1, PAR-2, and PAR-4 stimulates IL-6, IL-8, and prostaglandin E2 release from human respiratory epithelial cells. J. Immunol. 168, 3577-3585 (2002). (Pubitemid 34250428)
103. Asokananthan, N. et al. House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: the cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1. J. Immunol. 169, 4572-4578 (2002). (Pubitemid 35178236)
104. Page, K., Ledford, J. R., Zhou, P., Dienger, K. & Wills-Karp, M. Mucosal sensitization to German cockroach involves protease-activated receptor-2. Respir. Res. 11, 62 (2010).
105. Cocks, T. M. et al. A protective role for protease-activated receptors in the airways. Nature 398, 156-160 (1999).
106. Moffatt, J. D., Jeffrey, K. L. & Cocks, T. M. Protease-activated receptor-2 activating peptide SLIGRL inhibits bacterial lipopolysaccharide- induced recruitment of polymorphonuclear leukocytes into the airways of mice. Am. J. Respir. Cell. Mol. Biol. 26, 680-684 (2002). (Pubitemid 34557368)
107. Vergnolle, N. Clinical relevance of proteinase activated receptors (PARs) in the gut. Gut 54, 867-874 (2005). (Pubitemid 40732107)
108. Mule, F., Pizzuti, R., Capparelli, A. & Vergnolle, N. Evidence for the presence of functional protease activated receptor 4 (PAR4) in the rat colon. Gut 53, 229-234 (2004). (Pubitemid 38125510)
109. Hollenberg, M. D., Saifeddine, M., Al-Ani, B. & Gui, Y. Proteinase-activated receptor 4 (PAR4): action of PAR4-activating peptides in vascular and gastric tissue and lack of cross-reactivity with PAR1 and PAR2. Can. J. Physiol. Pharmacol. 77, 458-464 (1999). (Pubitemid 30339575)
110. Buresi, M. C., Buret, A. G., Hollenberg, M. D. & MacNaughton, W. K. Activation of proteinase-activated receptor 1 stimulates epithelial chloride secretion through a unique MAP kinase-and cyclo-oxygenase-dependent pathway. FASEB J. 16, 1515-1525 (2002). (Pubitemid 35154634)
111. Buresi, M. C. et al. Activation of proteinase-activated receptor-1 inhibits neurally evoked chloride secretion in the mouse colon in vitro. Am. J. Physiol. Gastrointest. Liver Physiol. 288, G337-G345 (2005). (Pubitemid 40129586)
112. Kong, W. et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc. Natl Acad. Sci. USA 94, 8884-8889 (1997). (Pubitemid 27335134)
113. van der Merwe, J. Q., Hollenberg, M. D. & MacNaughton, W. K. EGF receptor transactivation and MAP kinase mediate proteinase-activated receptor-2-induced chloride secretion in intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 294, G441-G451 (2008). (Pubitemid 351253333)
114. Lau, C., Lytle, C., Straus, D. S. & DeFea, K. A. Apical and basolateral pools of proteinase-activated receptor-2 direct distinct signaling events in the intestinal epithelium. Am. J. Physiol. Cell Physiol. 300, C113-C123 (2011).
115. Chin, A. C. et al. Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc. Natl Acad. Sci. USA 100, 11104-11109 (2003). (Pubitemid 37140159)
116. Mule, F., Baffi, M. C. & Cerra, M. C. Dual effect mediated by protease-activated receptors on the mechanical activity of rat colon. Br. J. Pharmacol. 136, 367-374 (2002). (Pubitemid 34620517)
117. Saifeddine, M., Al-Ani, B., Sandhu, S., Wijesuriya, S. J. & Hollenberg, M. D. Contractile actions of proteinase-activated receptor-derived polypeptides in guinea-pig gastric and lung parenchymal strips: evidence for distinct receptor systems. Br. J. Pharmacol. 132, 556-566 (2001). (Pubitemid 32143751)
118. Mule, F., Baffi, M. C., Capparelli, A. & Pizzuti, R. Involvement of nitric oxide and tachykinins in the effects induced by protease-activated receptors in rat colon longitudinal muscle. Br. J. Pharmacol. 139, 598-604 (2003). (Pubitemid 36819629)
119. Zhao, A. & Shea-Donohue, T. PAR-2 agonists induce contraction of murine small intestine through neurokinin receptors. Am. J. Physiol. Gastrointest. Liver Physiol. 285, G696-G703 (2003). (Pubitemid 37151231)
120. Kawabata, A. et al. In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse. Br. J. Pharmacol. 133, 1213-1218 (2001). (Pubitemid 32783480)
121. Cenac, N. et al. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 161, 1903-1915 (2002). (Pubitemid 35265547)
122. Hyun, E., Andrade-Gordon, P., Steinhoff, M. & Vergnolle, N. Protease-activated receptor-2 activation: a major actor in intestinal inflammation. Gut 57, 1222-1229 (2008).
123. Hyun, E., Andrade-Gordon, P., Steinhoff, M., Beck, P. L. & Vergnolle, N. Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis. Inflamm. Res. 59, 699-709 (2010).
124. Hansen, K. K. et al. A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc. Natl Acad. Sci. USA 102, 8363-8368 (2005). (Pubitemid 40800094)
125. Cottrell, G. S. et al. Protease-activated receptor 2, dipeptidyl peptidase I, and proteases mediate Clostridium difficile toxin A enteritis. Gastroenterology 132, 2422-2437 (2007). (Pubitemid 46890864)
126. Cenac, N. et al. Role for protease activity in visceral pain in irritable bowel syndrome. J. Clin. Invest. 117, 636-647 (2007). (Pubitemid 46348522)
127. Gecse, K. et al. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 57, 591-599 (2008).
128. Cenac, N. et al. Proteinase-activated receptor-1 is an anti-inflammatory signal for colitis mediated by a type 2 immune response. Inflamm. Bowel Dis. 11, 792-798 (2005). (Pubitemid 41368266)
129. Wee, J. L. et al. Protease-activated receptor-1 down-regulates the murine inflammatory and humoral response to Helicobacter pylori. Gastroenterology 138, 573-582 (2009).
130. Fiorucci, S. et al. Proteinase-activated receptor 2 is an anti-inflammatory signal for colonic lamina propria lymphocytes in a mouse model of colitis. Proc. Natl Acad. Sci. USA 98, 13936-13941 (2001). (Pubitemid 33116002)
131. Cattaruzza, F. et al. Protective effect of proteinase-activated receptor 2 activation on motility impairment and tissue damage induced by intestinal ischemia/reperfusion in rodents. Am. J. Pathol. 169, 177-188 (2006).
132. Striggow, F. et al. Four different types of protease-activated receptors are widely expressed in the brain and are up-regulated in hippocampus by severe ischemia. Eur. J. Neurosci. 14, 595-608 (2001). (Pubitemid 34625987)
133. Henrich-Noack, P., Riek-Burchardt, M., Baldauf, K., Reiser, G. & Reymann, K. G. Focal ischemia induces expression of protease-activated receptor1 (PAR1) and PAR3 on microglia and enhances PAR4 labeling in the penumbra. Brain Res. 1070, 232-241 (2006). (Pubitemid 43247762)
134. Suo, Z., Wu, M., Citron, B. A., Gao, C. & Festoff, B. W. Persistent protease-activated receptor 4 signaling mediates thrombin-induced microglial activation. J. Biol. Chem. 278, 31177-31183 (2003). (Pubitemid 36994633)
135. Wang, H., Ubl, J. J. & Reiser, G. Four subtypes of protease-activated receptors, co-expressed in rat astrocytes, evoke different physiological signaling. Glia 37, 53-63 (2002). (Pubitemid 34103094)
136. Scarisbrick, I. A., Isackson, P. J., Ciric, B., Windebank, A. J. & Rodriguez, M. MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J. Comp. Neurol. 431, 347-361 (2001). (Pubitemid 32115299)
137. Bernett, M. J. et al. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277, 24562-24570 (2002). (Pubitemid 34951983)
138. Sokolova, E. & Reiser, G. Prothrombin/thrombin and the thrombin receptors PAR-1 and PAR-4 in the brain: localization, expression and participation in neurodegenerative diseases. Thromb. Haemost. 100, 576-581 (2008).
139. Yoshida, S. & Shiosaka, S. Plasticity-related serine proteases in the brain. Int. J. Mol. Med. 3, 405-409 (1999).
140. Turgeon, V. L. & Houenou, L. J. The role of thrombin-like (serine) proteases in the development, plasticity and pathology of the nervous system. Brain Res. Brain Res. Rev. 25, 85-95 (1997). (Pubitemid 27459722)
141. Noorbakhsh, F., Vergnolle, N., Hollenberg, M. D. & Power, C. Proteinase-activated receptors in the nervous system. Nature Rev. Neurosci. 4, 981-990 (2003). (Pubitemid 37486674)
142. Luo, W., Wang, Y. & Reiser, G. Protease-activated receptors in the brain: receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res. Rev. 56, 331-345 (2007). (Pubitemid 350176599)
143. Vaughan, P. J., Pike, C. J., Cotman, C. W. & Cunningham, D. D. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J. Neurosci. 15, 5389-5401 (1995).
144. Donovan, F. M., Pike, C. J., Cotman, C. W. & Cunningham, D. D. Thrombin induces apoptosis in cultured neurons and astrocytes via a pathway requiring tyrosine kinase and RhoA activities. J. Neurosci. 17, 5316-5326 (1997). (Pubitemid 27300299)
145. Acharjee, S. et al. Proteinase-activated receptor-1 mediates dorsal root ganglion neuronal degeneration in HIV/AIDS. Brain 134, 3209-3221 (2011).
146. Gan, J., Greenwood, S. M., Cobb, S. R. & Bushell, T. J. Indirect modulation of neuronal excitability and synaptic transmission in the hippocampus by activation of proteinase-activated receptor-2. Br. J. Pharmacol. 163, 984-994 (2011).
147. Lohman, R. J., O'Brien, T. J. & Cocks, T. M. Protease-activated receptor-2 regulates trypsin expression in the brain and protects against
148. Lohman, R. J., Jones, N. C., O'Brien, T. J. & Cocks, T. M. A regulatory role for protease-activated receptor-2 in motivational learning in rats. Neurobiol. Learn. Mem. 92, 301-309 (2009).
149. Junge, C. E. et al. The contribution of protease-activated receptor 1 to neuronal damage caused by transient focal cerebral ischemia. Proc. Natl Acad. Sci. USA 100, 13019-13024 (2003). (Pubitemid 37340018)
150. Hamill, C. E., Mannaioni, G., Lyuboslavsky, P., Sastre, A. A. & Traynelis, S. F. Protease-activated receptor 1-dependent neuronal damage involves NMDA receptor function. Exp. Neurol. 217, 136-146 (2009).
151. Xue, M., Hollenberg, M. D., Demchuk, A. & Yong, V. W. Relative importance of proteinase-activated receptor-1 versus matrix metalloproteinases in intracerebral hemorrhage-mediated neurotoxicity in mice. Stroke 40, 2199-2204 (2009).
152. Boven, L. A. et al. Up-regulation of proteinase-activated receptor 1 expression in astrocytes during HIV encephalitis. J. Immunol. 170, 2638-2646 (2003). (Pubitemid 36245656)
153. Hamill, C. E. et al. Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Mol. Pharmacol. 72, 653-664 (2007). (Pubitemid 47347300)
154. Lee, E. J. et al. α-synuclein activates microglia by inducing the expressions of matrix metalloproteinases and the subsequent activation of protease-activated receptor-1. J. Immunol. 185, 615-623 (2010).
155. Nicole, O. et al. Activation of protease-activated receptor-1 triggers astrogliosis after brain injury. J. Neurosci. 25, 4319-4329 (2005). (Pubitemid 40628776)
156. Wang, Y., Luo, W., Stricker, R. & Reiser, G. Protease-activated receptor-1 protects rat astrocytes from apoptotic cell death via JNK-mediated release of the chemokine GRO/CINC-1. J. Neurochem. 98, 1046-1060 (2006). (Pubitemid 44127781)
157. Thiyagarajan, M., Fernandez, J. A., Lane, S. M., Griffin, J. H. & Zlokovic, B. V. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J. Neurosci. 28, 12788-12797 (2008).
158. Noorbakhsh, F. et al. Proteinase-activated receptor-2 induction by neuroinflammation prevents neuronal death during HIV infection. J. Immunol. 174, 7320-7329 (2005). (Pubitemid 40705702)
159. Noorbakhsh, F. et al. Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203, 425-435 (2006). (Pubitemid 43290851)
160. Afkhami-Goli, A. et al. Proteinase-activated receptor-2 exerts protective and pathogenic cell type-specific effects in Alzheimer's disease. J. Immunol. 179, 5493-5503 (2007).
161. Jin, G. et al. Deficiency of PAR-2 gene increases acute focal ischemic brain injury. J. Cereb. Blood Flow Metab. 25, 302-313 (2005). (Pubitemid 40315873)
162. Mao, Y., Zhang, M., Tuma, R. F. & Kunapuli, S. P. Deficiency of PAR4 attenuates cerebral ischemia/reperfusion injury in mice. J. Cereb. Blood Flow Metab. 30, 1044-1052 (2010).
163. Guo, H. et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron 41, 563-572 (2004). (Pubitemid 38253068)
164. Even-Ram, S. C. et al. Tumor cell invasion is promoted by activation of protease activated receptor-1 in cooperation with the αvβ5 integrin. J. Biol. Chem. 276, 10952-10962 (2001). (Pubitemid 38089274)
165. Even-Ram, S. et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nature Med. 4, 909-914 (1998). (Pubitemid 28364029)
166. Bar-Shavit, R. et al. PAR1 plays a role in epithelial malignancies: transcriptional regulation and novel signaling pathway. IUBMB Life 63, 397-402 (2011).
167. Nyberg, P., Ylipalosaari, M., Sorsa, T. & Salo, T. Trypsins and their role in carcinoma growth. Exp. Cell Res. 312, 1219-1228 (2006).
168. Soreide, K., Janssen, E. A., Korner, H. & Baak, J. P. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J. Pathol. 209, 147-156 (2006). (Pubitemid 43805409)
169. Zwicker, J. I., Furie, B. C. & Furie, B. Cancer-associated thrombosis. Crit. Rev. Oncol. Hematol. 62, 126-136 (2007). (Pubitemid 46575277)
170. Rickles, F. R. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol. Haemost. Thromb. 35, 103-110 (2006).
171. Trivedi, V. et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 137, 332-343 (2009).
172. Boire, A. et al. PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313 (2005). (Pubitemid 40222426)
173. Salah, Z. et al. Identification of a novel functional androgen response element within hPar1 promoter: implications to prostate cancer progression. FASEB J. 19, 62-72 (2005). (Pubitemid 40069921)
174. Ramsay, A. J. et al. Kallikrein-related peptidase 4 (KLK4) initiates intracellular signaling via protease-activated receptors (PARs).
175. Gratio, V. et al. Kallikrein-related peptidase 14 acts on proteinase-activated receptor 2 to induce signaling pathway in colon cancer cells. Am. J. Pathol. 179, 2625-2636 (2011).
176. Gratio, V. et al. Kallikrein-related peptidase 4: a new activator of the aberrantly expressed protease-activated receptor 1 in colon cancer cells. Am. J. Pathol. 176, 1452-1461 (2010).
177. Krenzer, S. et al. Expression and function of the kallikrein-related peptidase 6 in the human melanoma microenvironment. J. Invest. Dermatol. 131, 2281-2288 (2011).
178. Wang, J., Boerma, M., Kulkarni, A., Hollenberg, M. D. & Hauer-Jensen, M. Activation of protease activated receptor 2 by exogenous agonist exacerbates early radiation injury in rat intestine. Int. J. Radiat. Oncol. Biol. Phys. 77, 1206-1212 (2010).
179. Vergnolle, N. Protease-activated receptors as drug targets in inflammation and pain. Pharmacol. Ther. 123, 292-309 (2009).
180. Sevigny, L. M. et al. Interdicting protease-activated receptor-2-driven inflammation with cell-penetrating pepducins. Proc. Natl Acad. Sci. USA 108, 8491-8496 (2011).
181. Dowal, L. et al. Identification of an antithrombotic allosteric modulator that acts through helix 8 of PAR1. Proc. Natl Acad. Sci. USA 108, 2951-2956 (2011).
182. Ruda, E. M., Scrutton, M. C., Manley, P. W. & Tuffin, D. P. Thrombin receptor antagonists: structure-activity relationships for the platelet thrombin receptor and effects on prostacyclin synthesis by human umbilical vein endothelial cells. Biochem. Pharmacol. 39, 373-381 (1990). (Pubitemid 20025627)
183. Ruda, E. M., Petty, A., Scrutton, M. C., Tuffin, D. P. & Manley, P. W. Identification of small peptide analogues having agonist and antagonist activity at the platelet thrombin receptor. Biochem. Pharmacol. 37, 2417-2426 (1988).
184. Andrade-Gordon, P. et al. Design, synthesis, and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc. Natl Acad. Sci. USA 96, 12257-12262 (1999). (Pubitemid 29513488)
185. Maryanoff, B. E., Zhang, H. C., Andrade-Gordon, P. & Derian, C. K. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1). Curr. Med. Chem. Cardiovasc. Hematol. Agents 1, 13-36 (2003).
186. Andrade-Gordon, P. et al. Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats. J. Pharmacol. Exp. Ther. 298, 34-42 (2001). (Pubitemid 32574507)
187. Derian, C. K. et al. Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. 304, 855-861 (2003). (Pubitemid 36152366)
188. Chackalamannil, S. et al. Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents. J. Med. Chem. 48, 5884-5887 (2005). (Pubitemid 41324598)
189. Chackalamannil, S. et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J. Med. Chem. 51, 3061-3064 (2008). (Pubitemid 351821864)
190. Becker, R. C. et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled Phase II study. Lancet 373, 919-928 (2009).
191. TRA*CER, Executive and Steering Committees. The thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA*CER) trial: study design and rationale. Am. Heart J. 158, 327-334 (2009).
192. Morrow, D. A. et al. Evaluation of a novel antiplatelet agent for secondary prevention in patients with a history of atherosclerotic disease: design and rationale for the thrombin-receptor antagonist in secondary prevention of atherothrombotic ischemic events (TRA 2 ?P)-TIMI 50 trial. Am. Heart J. 158, 335-341 (2009).
193. Tricoci, P. et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.13 Nov 2011 (doi:10.1056/NEJMoa1109719).
194. Feistritzer, C. & Riewald, M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood 105, 3178-3184 (2005).
195. Schuepbach, R. A., Feistritzer, C., Fernandez, J. A., Griffin, J. H. & Riewald, M. Protection of vascular barrier integrity by activated protein C in murine models depends on protease-activated receptor-1. Thromb. Haemost. 101, 724-733 (2009).
196. Kaneider, N. C. et al. 'Role reversal' for the receptor PAR1 in sepsis-induced vascular damage. Nature Immunol. 8, 1303-1312 (2007). (Pubitemid 350131169)
197. Serebruany, V. L., Kogushi, M., Dastros-Pitei, D., Flather, M. & Bhatt, D. L. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb. Haemost. 102, 111-119 (2009).
198. O'Donoghue, M. L. et al. Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of thrombin-acute coronary syndromes trial. Circulation 123, 1843-1853 (2011).
199. Wiviott, S. D. et al. Randomized trial of atopaxar in the treatment of patients with coronary artery disease: the lessons from antagonizing the cellular effect of thrombin-coronary artery disease trial. Circulation 123, 1854-1863 (2011).
200. Goto, S., Ogawa, H., Takeuchi, M., Flather, M. D. & Bhatt, D. L. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J. 31, 2601-2613 (2010).
201. Chieng-Yane, P. et al. Protease-activated receptor-1 antagonist F 16618 reduces arterial restenosis by down-regulation of tumor necrosis factor α and matrix metalloproteinase 7 expression, migration, and proliferation of vascular smooth muscle cells. J. Pharmacol. Exp. Ther. 336, 643-651 (2011).
202. Perez, M. et al. Discovery of novel protease activated receptors 1 antagonists with potent antithrombotic activity in vivo. J. Med. Chem. 52, 5826-5836 (2009).
203. Planty, B. et al. Exploration of a new series of PAR1 antagonists. Bioorg. Med. Chem. Lett. 20, 1735-1739 (2010).
204. Al-Ani, B., Saifeddine, M., Wijesuriya, S. J. & Hollenberg, M. D. Modified proteinase-activated receptor-1 and-2 derived peptides inhibit proteinase-activated receptor-2 activation by trypsin. J. Pharmacol. Exp. Ther. 300, 702-708 (2002).
205. Goh, F. G., Ng, P. Y., Nilsson, M., Kanke, T. & Plevin, R. Dual effect of the novel peptide antagonist K-14585 on proteinase-activated receptor-2-mediated signalling. Br. J. Pharmacol. 158, 1695-1704 (2009).
206. Lohman, R. J. et al. Antagonism of protease activated receptor 2 protects against experimental colitis. J. Pharmacol. Exp. Ther. 25 Oct 2011 (doi:10.1124/jpet.111.187062).
207. Barry, G. D. et al. Novel agonists and antagonists for human protease activated receptor 2. J. Med. Chem. 53, 7428-7440 (2010).
208. Suen, J. Y., Gardiner, B., Grimmond, S. & Fairlie, D. P. Profiling gene expression induced by protease-activated receptor 2 (PAR2) activation in human kidney cells. PLoS ONE 5, e13809 (2010).
209. Suen, J. Y. Regulating Protease Activated Receptor 2. Thesis, Univ. Queensland, Brisbane, Australia (2009).
210. Hollenberg, M. D. & Saifeddine, M. Proteinase-activated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4-derived peptides. Can. J. Physiol. Pharmacol. 79, 439-442 (2001). (Pubitemid 32747883)
211. Wu, C. C. et al. Selective inhibition of protease-activated receptor 4-dependent platelet activation by YD-3. Thromb. Haemost. 87, 1026-1033 (2002).
212. Wu, C. C. et al. The role of PAR4 in thrombin-induced thromboxane production in human platelets. Thromb. Haemost. 90, 299-308 (2003).
213. Al-Ani, B. et al. Proteinase-activated receptor 2 (PAR(2)): development of a ligand-binding assay correlating with activation of PAR(2) by PAR(1)-and PAR(2)-derived peptide ligands. J. Pharmacol. Exp. Ther. 290, 753-760 (1999). (Pubitemid 29344572)
214. O'Brien, P. J. et al. Thrombin responses in human endothelial cells. Contributions from receptors other than PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1. J. Biol. Chem. 275, 13502-13509 (2000). (Pubitemid 30257415)
215. Tressel, S. L. et al. Pharmacology, biodistribution, and efficacy of GPCR-based pepducins in disease models. Methods Mol. Biol. 683, 259-275 (2010).
216. Covic, L., Misra, M., Badar, J., Singh, C. & Kuliopulos, A. Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation. Nature Med. 8, 1161-1165 (2002). (Pubitemid 35175972)
217. Covic, L., Gresser, A. L., Talavera, J., Swift, S. & Kuliopulos, A. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl Acad. Sci. USA 99, 643-648 (2002). (Pubitemid 34106565)
218. Yang, E. et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res. 69, 6223-6231 (2009).
219. Kenakin, T. P. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nature Rev. Drug Discov. 8, 617-626 (2009).
220. Hanyaloglu, A. C. & von Zastrow, M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu. Rev. Pharmacol. Toxicol. 48, 537-568 (2008). (Pubitemid 351738163)
221. Marchese, A., Paing, M. M., Temple, B. R. & Trejo, J. G protein-coupled receptor sorting to endosomes and lysosomes. Annu. Rev. Pharmacol. Toxicol. 48, 601-629 (2008). (Pubitemid 351738165)
222. Chen, C. H., Paing, M. M. & Trejo, J. Termination of protease-activated receptor-1 signaling by β-arrestins is independent of receptor phosphorylation. J. Biol. Chem. 279, 10020-10031 (2004). (Pubitemid 38372605)
223. Paing, M. M., Temple, B. R. & Trejo, J. A tyrosine-based sorting signal regulates intracellular trafficking of protease-activated receptor-1: multiple regulatory mechanisms for agonist-induced G protein-coupled receptor internalization. J. Biol. Chem. 279, 21938-21947 (2004). (Pubitemid 38679384)
224. Wang, Y., Zhou, Y., Szabo, K., Haft, C. R. & Trejo, J. Down-regulation of protease-activated receptor-1 is regulated by sorting nexin 1. Mol. Biol. Cell 13, 1965-1976 (2002). (Pubitemid 34651486)
225. Swift, S. et al. A novel protease-activated receptor-1 interactor, bicaudal D1, regulates G protein signaling and internalization. J. Biol. Chem. 285, 11402-11410 (2010).
226. Defea, K., Schmidlin, F., Dery, O., Grady, E. F. & Bunnett, N. W. Mechanisms of initiation and termination of signalling by neuropeptide receptors: a comparison with the proteinase-activated receptors. Biochem. Soc. Trans. 28, 419-426 (2000).
227. Roosterman, D., Schmidlin, F. & Bunnett, N. W. Rab5a and rab11a mediate agonist-induced trafficking of protease-activated receptor 2. Am. J. Physiol. Cell Physiol. 284, C1319-C1329 (2003). (Pubitemid 36457413)
228. Bernatowicz, M. S. et al. Development of potent thrombin receptor antagonist peptides. J. Med. Chem. 39, 4879-4887 (1996). (Pubitemid 26422501)
229. Damiano, B. P., Derian, C. K., Maryanoff, B. E., Zhang, H. C. & Gordon, P. A. RWJ-58259: a selective antagonist of protease activated receptor-1. Cardiovasc. Drug Rev. 21, 313-326 (2003). (Pubitemid 38029966)
230. Kato, Y. et al. Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig. Eur. J. Pharmacol. 473, 163-169 (2003). (Pubitemid 36929880)
231. Suen, J. Y. et al. Modulating human proteinase activated receptor 2 with a novel antagonist (GB88) and agonist (GB110). Br. J. Pharmacol. 1 Aug 2011 (doi:10.1111/j.1476-5381.2011.01610.x).
232. Gardell, L. R. et al. Identification and characterization of novel small-molecule protease-activated receptor 2 agonists. J. Pharmacol. Exp. Ther. 327, 799-808 (2008).
233. Kanke, T. et al. Novel antagonists for proteinase-activated receptor 2: inhibition of cellular and vascular responses in vitro and in vivo. Br. J. Pharmacol. 158, 361-371 (2009).
234. Chen, H. S. et al. Synthesis and antiplatelet activity of ethyl 4-(1-benzyl-1H-indazol-3-yl)benzoate (YD-3) derivatives. Bioorg. Med. Chem. 16, 1262-1278 (2008).
235. Wu, C. C. et al. YD-3, a novel inhibitor of protease-induced platelet activation. Br. J. Pharmacol. 130, 1289-1296 (2000).